KalVista Pharmaceuticals (KALV) Gains from Investment Securities (2014 - 2025)
KalVista Pharmaceuticals' (KALV) quarterly Gains from Investment Securities came in at $725000.0 in Q3 2025, up 128.71% year-on-year from $317000.0 in Q3 2024, and up 96.48% quarter-over-quarter from $369000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Gains from Investment Securities (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals has disclosed Gains from Investment Securities across 11 years of filings, most recently posting $725000.0 for Q3 2025.
- Gains from Investment Securities for Q3 2025 came in at $725000.0, up 128.71% year-over-year; the trailing twelve-month figure through Jul 2025 was $1.4 million (up 724.85% YoY), and the FY2025 annual result was $1.6 million, up 863.58% from the prior year.
- Gains from Investment Securities came in at $725000.0 for Q3 2025 at KalVista Pharmaceuticals, up from $369000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.3 million in Q1 2023 to a low of -$968000.0 in Q2 2024.
- The 5-year median for Gains from Investment Securities is -$16000.0 (2022), against an average of $127705.9.
- Across the five-year window, Gains from Investment Securities plunged 630.77% in 2022 and soared 2062.5% in 2023, its largest moves.
- KalVista Pharmaceuticals' Gains from Investment Securities stood at -$97000.0 in 2021, then rose by 28.87% to -$69000.0 in 2022, then jumped by 962.32% to $595000.0 in 2023, then tumbled by 108.4% to -$50000.0 in 2024, then soared by 1550.0% to $725000.0 in 2025.
- The last three Gains from Investment Securities figures came in at $725000.0 (Q3 2025), $369000.0 (Q2 2025), and -$50000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 725,000.00 |
| Jul 31, 2025 | 725,000.00 |
| Apr 30, 2025 | 369,000.00 |
| Apr 30, 2025 | 369,000.00 |
| Oct 31, 2024 | -50,000.00 |
| Oct 31, 2024 | -50,000.00 |
| Jul 31, 2024 | 317,000.00 |
| Jul 31, 2024 | 317,000.00 |
| Apr 30, 2024 | -968,000.00 |
| Apr 30, 2024 | -968,000.00 |
| Jan 31, 2024 | 221,000.00 |
| Jan 31, 2024 | 221,000.00 |
| Oct 31, 2023 | 595,000.00 |
| Oct 31, 2023 | 595,000.00 |
| Jul 31, 2023 | 314,000.00 |
| Jul 31, 2023 | 314,000.00 |
| Jan 31, 2023 | 1.28 Mn |
| Jan 31, 2023 | 1.28 Mn |
| Oct 31, 2022 | -69,000.00 |
| Oct 31, 2022 | -69,000.00 |